

Disparities in Targeted Immune Modulating (TIM) Treatment for Elderly Compared to Younger Patients with Psoriatic Arthritis (PSA)

1 University of Alabama at Birmingham, AL, USA, 2 Trio Health Analytics, Louisville, CO, USA, 3 Brigham and Women's Hospital, Harvard Medical School, MA, USA, 4 Kansas City Physician Partners, Kansas City, MO, USA, 5 Arizona Arthritis & Rheumatology Associates, P.C., AZ, USA, 6 Articularis Healthcare, SC, USA

1. BACKGROUND AND AIM

Targeted immunomodulating (TIM) therapies (JAK inhibitors and biologics) are as effective in the elderly as in younger patients with PsA. However, balancing the greater comorbidity burden associated with aging may influence prescribing patterns as clinicians seek to avoid serious adverse events in the ≥65-year-old population. Here, we examine associations between age and TIM treatment patterns in a large US community rheumatology practice registry.

2. METHODS

The American Rheumatology Network (ARN)-TRIO Rheumatology registry consists of EMR (fielded and open text), lab, procedure, infusion, medical claims, and specialty pharmacy data generated in care of >75,000 patients by ARN, a network of independent practices with >200 rheumatologists across the US. This study analyzed patients diagnosed with PsA and who initiated care with conventional synthetic DMARD (csDMARD) monotherapy between Jan 2014 to Nov 2019 with follow-up of ≥ 6 months. Disease Activity Scores (DAS) were calculated using CDAI or RAPID-3, with priority given to CDAI. Differences in time to initiation of TIM containing regimens were analyzed with KM curves and associated Log-Rank Test for difference in hazard. Analysis performed on unmatched cohort and matched cohort, generated through 2:1 matching through propensity scores with 0.1 max caliper. Patients were matched on gender, race, and ethnicity.

3. RESULTS

524 patients met all inclusion criteria. Age groups <65y (387, 74%) and ≥65y (137, 26%) were not significantly different by gender, race, ethnicity, hypertension, or baseline DAS. [Table 1] Diabetes and osteoporosis were significantly higher in the \geq 65y group among unmatched comparisons, with osteoporosis persisting in matched comparisons. [Table 1] 495 (94%) of patients initiated TIM therapy within 2 years of first csDMARD regimen. No differences in time to initiation of TIM were observed by baseline DAS (p = 0.11) or payer type (p = 0.29). [not shown] Via KM Curves, patients in the older cohort remained on csDMARD regimens significantly longer than younger patients, 6.8 vs. 4.0 months [p=0.019] .[Figure 1] Upon treatment with TIM therapies, patients \geq 65y were more likely to receive infused therapy +/csDMARDS (22% ≥65y vs 12% <65y, p<0.01). [Table 2]

4. CONCLUSION

Overall, comorbidity burden is an important consideration in timing and choice of targeted therapies. These data suggest that differences in treatment exist between age groups even when comorbidity differences are minimized and raise the possibility to age bias may influence care for $\geq 65y$ population.

Jasvinder Singh¹, Andrew Frick², Simon Helfgott³, Kent Kwas Huston⁴, Nehad Soloman⁵, John Tesser⁵, Colin Edgerton⁶

<table-container>Unate of the set of the set</table-container>	TABLE 1 PATIENT DEMOGRAPHICS AT ENROLLMENT								
<table-container>Index certain IntermediationTotalIndex</table-container>			Unmatche	ed		Matched			
<table-container>V524387137600393261132and224 (da.s)237 (da.s)237 (da.s)247 (da.s)248 (da.s)155 (da.s)249 (da.s)249 (da.s)White343/57492 (da.s)249 (da.s)<th>Characteristic</th><th>Total</th><th><65</th><th>≥65</th><th>р</th><th>Total</th><th><65</th><th>≥65</th><th>р</th></table-container>	Characteristic	Total	<65	≥65	р	Total	<65	≥65	р
Remain324 (61.8)237 (61.2)87 (63.2)97 (63.2)248 (63.1)165 (63.2)83 (63.2)97 (93.1)Race343 (357)249 (58.3)99 (97)0.88261 (27.0)171 (7.0)90 (9.3)20.99Black(355 (28.8)8/260 (31.1)2/97 (21.1)7/27 (26.5)5/177 (28.1)2/93 (24.1)7/27 (18.1)90 (9.3)2/93 (24.1)Black(355 (28.1)3/260 (12.1)1/97 (13.1)(12.2)7/27 (20.5)5/177 (28.1)1/93 (14	Ν	524	387	137		393	261	132	
Raceimage: stateimage: state	Female	324 (61.8)	237 (61.2)	87 (63.5)	0.683	248 (63.1)	165 (63.2)	83 (62.9)	>0.99
White343/357 (96.1)249/200 (95.8)94/97 (96.3)0.88 (96.7)261/270 (96.7)171/17 (96.6)90/93 (96.8)90.99 (96.8)Black10/357 (2.8)8/260 (3.1)2/97 (2.1)7/270 (2.6)5/177 (2.8)7/20 (2.1)1/30 (1.1)1Other Race4/357 (1.1)3/260 (2.1)1/97 (1.0)1/270 (0.7)1/177 (0.6)1/97 (1.0)1/270 (0.7)1/177 (0.1)1/93 (1.0)1/03 (1.	Race								
Black 10/357 (2.8) 8/260 (3.1) 2/97 (2.1) 1/27 (2.6) 5/177 (2.8) 2/93 (2.1) Other Race 4/357 (1.1) 3/260 (1.2) 1/97 (1.8) 1/27 (0.2) 1/17 (0.6) 1/93 (1.1) 1/17 (0.1) <th1 (0.1)<="" 17="" th=""></th1>	White	343/357 (96.1)	249/260 (95.8)	94/97 (96.9)	0.888	261/270 (96.7)	171/177 (96.6)	90/93 (96.8)	>0.99
Other Race 4/357 (1.1) 3/260 (1.2) 1/97 (1.0) 1/270 (0.7) 1/177 (0.6) 1/93 (1.1) Hispanic or Latio 1/271 (3.7) 9/192 (4.7) 1/79 (1.8) 0.29 7/205 (3.4) 6/130 (4.6) 1/75 (1.8) 0.426 Age Group 180 (34.4) 180 (46.5) C 123 (31.3) 123 (47.1) C 1/10000 1/10000 1/10000 1/10000 1/10000 1/10000	Black	10/357 (2.8)	8/260 (3.1)	2/97 (2.1)		7/270 (2.6)	5/177 (2.8)	2/93 (2.2)	
Hispanic or Latio10/271 (3.7)9/192 (4.7)179 (1.3)0.297/205 (3.4)6/130 (4.6)175 (1.3)0.426Age Group180 (34.4)180 (46.5)11121 (31.3)123 (47.1)111(15, 50)207 (33.)207 (33.5)111 </td <td>Other Race</td> <td>4/357 (1.1)</td> <td>3/260 (1.2)</td> <td>1/97 (1.0)</td> <td></td> <td>2/270 (0.7)</td> <td>1/177 (0.6)</td> <td>1/93 (1.1)</td> <td></td>	Other Race	4/357 (1.1)	3/260 (1.2)	1/97 (1.0)		2/270 (0.7)	1/177 (0.6)	1/93 (1.1)	
Age GroupIdea	Hispanic or Latin	o 10/271 (3.7)	9/192 (4.7)	1/79 (1.3)	0.29	7/205 (3.4)	6/130 (4.6)	1/75 (1.3)	0.426
(18,50)180 (34.4)180 (46.5)(123 (31.3)123 (37.1)(137 (37.1))(137 (37.1))(137 (37.1))(138 (52.1))(138	Age Group								
(50,65)207 (39.5)207 (53.5)Image: Second S	(18,50)	180 (34.4)	180 (46.5)			123 (31.3)	123 (47.1)		
137 (65,100) 137 (26.1) 137 (100.0 132 (33.6) 132 (100.0 132 (100.0)Payer Type 12 132 (30.1) 132 (30.1) 132 (30.1) 132 (30.1) 132 (30.1) 132 (30.1) 100 (100) 362 (69.1) 327 (84.5) 35 (25.5) 40.01 257 (65.4) 222 (85.1) 35 (26.5) 40.01 100 (100) 93 (17.7) 164 (10.1) 77 (56.2) 84 (21.4) 12 (4.6) 72 (54.5) <th< td=""><td>(50<i>,</i>65)</td><td>207 (39.5)</td><td>207 (53.5)</td><td></td><td></td><td>138 (35.1)</td><td>138 (52.9)</td><td></td><td></td></th<>	(50 <i>,</i> 65)	207 (39.5)	207 (53.5)			138 (35.1)	138 (52.9)		
Payer TypeImage: space typeImage: sp	(65,100)	137 (26.1)		137 (100.0)		132 (33.6)		132 (100.0)	
Commercial 362 (69.1) 327 (84.5) 35 (25.5) <0.001 257 (65.4) 222 (85.1) 35 (26.5) <0.001 Medicare 93 (17.7) 16 (4.1) 77 (56.2) 84 (21.4) 12 (4.6) 72 (54.5) <0.001 Medicare 36 (6.9) 13 (3.4) 23 (16.8) 30 (7.6) 7 (2.7) 23 (17.4) Other 33 (6.3) 31 (8.0) 2 (1.5) 22 (5.6) 20 (7.7) 2 (1.5) Other 33 (6.3) 31 (8.0) 2 (1.5) 22 (5.6) 20 (7.7) 2 (1.5) Other 33 (6.3) 31 (8.0) 2 (1.5) 22 (5.6) 20 (7.7) 2 (1.5) Mean Remission 19/175 (10.9) 2/128 (9.4) 7/47 (14.9) 0.711 16(125 (12.8) 9/80 (11.2) 7/45 (15.6) 0.872 (15.0)	Payer Type								
Medicare Advantage 93 (17.7) 16 (4.1) 77 (56.2) 84 (21.4) 12 (4.6) 72 (54.5) Medicare Advantage 36 (6.9) 13 (3.4) 23 (16.8) 23 (07.6) 7 (2.7) 23 (17.4) 16 (17.7) Other 33 (6.3) 31 (8.0) 2 (1.5) 22 (5.6) 20 (7.7) 2 (1.5) 2 (1.5) Disease Assessment Score 19/175 12/128 (9.4) 7/47 (14.9) 0.71 16/125 (12.8) 9/80 (11.2) 7/45 (15.6) 0.872 Near Remission 19/175 (15.4) 21/128 (16.4) 6/47 (12.8) 0.71 (16.0) 14/80 (17.5) 6/45 (15.6) 7/45 (15.6) 0.872 Moderate 59/175 (15.4) 21/128 (16.4) 15/47 (12.8) 38/125 (30.4) 24/80 (17.5) 14/45 (31.1) 14/45 (31.1) 14/45 (30.0) 14/45 (31.1) 14/45 (40.0) 14/45 (40.	Commercial	362 (69.1)	327 (84.5)	35 (25.5)	<0.001	257 (65.4)	222 (85.1)	35 (26.5)	< 0.001
Medicare Advantage36 (6.9)13 (3.4)23 (16.8)30 (7.6)7 (2.7)23 (17.4)23 (17.4)Other33 (6.3)31 (8.0)2 (1.5)222 (5.6)20 (7.7)2 (1.5)1Sease Sessesment Score	Medicare	93 (17.7)	16 (4.1)	77 (56.2)		84 (21.4)	12 (4.6)	72 (54.5)	
Other 33 (6.3) 31 (8.0) 2 (1.5) 22 (5.6) 20 (7.7) 2 (1.5) 2 (1.5) Disease Assessment Score	Medicare Advantage	36 (6.9)	13 (3.4)	23 (16.8)		30 (7.6)	7 (2.7)	23 (17.4)	
Assessment ScoreImage: sease	Other	33 (6.3)	31 (8.0)	2 (1.5)		22 (5.6)	20 (7.7)	2 (1.5)	
Near Remission 19/175 (10.9) 12/128 (9.4) 7/47 (14.9) 0.711 16/125 (12.8) 9/80 (11.2) 7/45 (15.6) 0.872 Low 27/175 (15.4) 21/128 (16.4) 6/47 (12.8) 20/125 (16.0) 14/80 (17.5) 6/45 (13.3) 6/45 Moderate 59/175 (33.7) 44/128 (34.4) 15/47 (31.9) 38/125 (30.4) 24/80 (30.0) 14/45 (31.1) 14/45 (30.0) 14/45 (31.1) 14/45 (40.8) 14/45 (40.2) 14/45 (40.0) 18/45 (40.0)	Disease Assessment Score	ł							
Low27/175 (15.4)21/128 (16.4)6/47 (12.8)20/125 (16.0)14/80 (17.5)6/45 (13.3)Moderate59/175 (33.7)44/128 (34.4)15/47 (31.9)38/125 (30.4)24/80 (30.0)14/45 (31.1)Severe70/175 (40.0)51/128 (39.8)19/47 (40.4)51/125 (40.4)33/80 (41.2)18/45 (40.0)Deteoporosis BL Depression BL26 (5.0)12 (3.1)14 (10.2) (40.2)0.00221 (5.3)9 (3.4)12 (9.1)0.03Deteoporosis BL Depression BL11 (2.1)7 (1.8) (13 (2.5)4 (2.9) (3 (3.1)0.0076 (1.5)3 (1.1)3 (2.3)0.408Hypertension BL13 (2.5)5 (1.3)8 (5.8) (14.7)0.0076 (1.5)3 (1.1)3 (2.3)0.408	Near Remission	19/175 (10.9)	12/128 (9.4)	7/47 (14.9)	0.711	16/125 (12.8)	9/80 (11.2)	7/45 (15.6)	0.872
Moderate59/175 (33.7)44/128 (34.4)15/47 (31.9)38/125 (30.4)24/80 (30.0)14/45 (31.1)Severe70/175 (40.0)51/128 (39.8)19/47 (40.4)51/125 (40.4)33/80 (41.2)18/45 (40.8)18/45 (40.2)Steoporosis BL26 (5.0)12 (3.1)14 (10.2)0.00221 (5.3)9 (3.4)12 (9.1)0.03Depression BL11 (2.1)7 (1.8)4 (2.9)0.4896 (1.5)3 (1.1)3 (2.3)0.408Diabetes BL13 (2.5)5 (1.3)8 (5.8)0.0076 (1.5)3 (1.1)3 (2.3)0.408Hypertension BL78 (14.9)57 (14.7)21 (15.3)0.88946 (11.7)30 (11.5)16 (12.1)0.869	Low	27/175 (15.4)	21/128 (16.4)	6/47 (12.8)		20/125 (16.0)	14/80 (17.5)	6/45 (13.3)	
Severe70/175 (40.0)51/128 (39.8)19/47 (40.4)51/125 (40.8)33/80 (41.2)18/45 (40.0)Dsteoporosis BL26 (5.0)12 (3.1)14 (10.2)0.00221 (5.3)9 (3.4)12 (9.1)0.03Depression BL11 (2.1)7 (1.8)4 (2.9)0.4896 (1.5)3 (1.1)3 (2.3)0.408Diabetes BL13 (2.5)5 (1.3)8 (5.8)0.0076 (1.5)3 (1.1)3 (2.3)0.408Hypertension BL78 (14.9)57 (14.7)21 (15.3)0.88946 (11.7)30 (11.5)16 (12.1)0.869	Moderate	59/175 (33.7)	44/128 (34.4)	15/47 (31.9)		38/125 (30.4)	24/80 (30.0)	14/45 (31.1)	
Osteoporosis BL26 (5.0)12 (3.1)14 (10.2)0.00221 (5.3)9 (3.4)12 (9.1)0.03Depression BL11 (2.1)7 (1.8)4 (2.9)0.4896 (1.5)3 (1.1)3 (2.3)0.408Diabetes BL13 (2.5)5 (1.3)8 (5.8)0.0076 (1.5)3 (1.1)3 (2.3)0.408Hypertension BL78 (14.9)57 (14.7)21 (15.3)0.88946 (11.7)30 (11.5)16 (12.1)0.869	Severe	70/175 (40.0)	51/128 (39.8)	19/47 (40.4)		51/125 (40.8)	33/80 (41.2)	18/45 (40.0)	
Depression BL11 (2.1)7 (1.8)4 (2.9)0.4896 (1.5)3 (1.1)3 (2.3)0.408Diabetes BL13 (2.5)5 (1.3)8 (5.8)0.0076 (1.5)3 (1.1)3 (2.3)0.408Hypertension BL78 (14.9)57 (14.7)21 (15.3)0.88946 (11.7)30 (11.5)16 (12.1)0.869	Osteoporosis BL	26 (5.0)	12 (3.1)	14 (10.2)	0.002	21 (5.3)	9 (3.4)	12 (9.1)	0.03
Diabetes BL 13 (2.5) 5 (1.3) 8 (5.8) 0.007 6 (1.5) 3 (1.1) 3 (2.3) 0.408 Hypertension BL 78 (14.9) 57 (14.7) 21 (15.3) 0.889 46 (11.7) 30 (11.5) 16 (12.1) 0.869	Depression BL	11 (2.1)	7 (1.8)	4 (2.9)	0.489	6 (1.5)	3 (1.1)	3 (2.3)	0.408
Hypertension BL78 (14.9)57 (14.7)21 (15.3)0.88946 (11.7)30 (11.5)16 (12.1)0.869	Diabetes BL	13 (2.5)	5 (1.3)	8 (5.8)	0.007	6 (1.5)	3 (1.1)	3 (2.3)	0.408
	Hypertension BL	78 (14.9)	57 (14.7)	21 (15.3)	0.889	46 (11.7)	30 (11.5)	16 (12.1)	0.869

TABLE 2 **REGIMEN DISTRIBUTION AT TIM INITIATION**

Regimen Combination	Total	<65	≥65	
TIM	129/524 (24.6)	92/387 (23.8)	37/137 (27.0)	
csDMARD + TIM	388/524 (74.4)	292/387 (75.5)	98/137 (71.5)	
CS DMARD + TIM + TIM	4/524 (0.8)	3/387 (0.8)	1/137 (0.7)	
TIM + TIM	1/524 (0.2)	-	1/137 (0.7)	
Regimens containing Infused TIM	-	45/387 (11.6)	30/137 (21.9)	

